RS53872B2 - Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana - Google Patents

Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana

Info

Publication number
RS53872B2
RS53872B2 RS20150093A RSP20150093A RS53872B2 RS 53872 B2 RS53872 B2 RS 53872B2 RS 20150093 A RS20150093 A RS 20150093A RS P20150093 A RSP20150093 A RS P20150093A RS 53872 B2 RS53872 B2 RS 53872B2
Authority
RS
Serbia
Prior art keywords
peptide
cancer
cell
nucleic acid
expression vector
Prior art date
Application number
RS20150093A
Other languages
English (en)
Inventor
Hans-Georg Prof Dr Rammensee
Stefan Prof Dr Stevanovic
Cécile Dr Gouttefanges
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39789337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS53872(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of RS53872B1 publication Critical patent/RS53872B1/sr
Publication of RS53872B2 publication Critical patent/RS53872B2/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (1)

  1. PATENTNI ZAHTEVI
    1. Peptid koji sadrži aminokiselinsku sekvencu ID br. SEKV 1
    (TLGEFLKLDRERAKN).
    2. Peptid u skladu sa patentnim zahtevom 1, naznačeno time što navedeni peptid sekvence ID br.
    SEK 1 ima sposobnost da se veže za molekul HLA alela HLA-DR.
    3. Peptid u skladu sa patentnim zahtevom 2, naznačeno time što je navedeni peptid sposoban da stimuliše CD4 ili CD8 T ćelije.
    4. Fuzioni protein, koji se sastoji od peptida u skladu sa bilo kojim od patentnih zahteva od 1 do 3 fuzionisan sa N-terminalnim aminokiselinama HLA-DR antigen-povezanog nepromenljivog lanca (Ii).
    5. Nukleinska kiselina koja kodira peptid u skladu sa bilo kojim od patentnih zahteva od 1 do 4 ili vektor ekspresije sposoban da eksprimira navedenu nukleinsku kiselinu.
    6. Peptid u skladu sa bilo kojim od patentnih zahteva od 1 do 4 ili nukleinska kiselina ili vektor ekspresije u skladu sa patentnim zahtevom 5 za upotrebu u medicini.
    7. Ćelija domaćin koja sadrži nukleinsku kiselinu ili vektor ekspresije u skladu sa patentnim zahtevom 5, naznačeno time što je navedena ćelija domaćin poželjno
    antigen-prezentujuća ćelija koja predstavlja antigen, naročito dendritična ćelija ili ćelija koja predstavlja antigen.
    8. Metod za proizvodnju peptida u skladu sa bilo kojim od patentnih zahteva od 1 do 4, pri čemu metod obuhvata kultiviranje ćelije domaćina u skladu sa patentnim zahtevom 7 koja eksprimira nukleinsku kiselinu ili vektor ekspresije u skladu sa patentnim zahtevom 5, i izolaciju peptida iz ćelije domaćina ili medijuma za njeno kultiviranje.
    10. Peptid u skladu sa bilo kojim od patentnih zahteva od 1 do 4, nukleinska kiselina ili vektor ekspresije u skladu sa patentnim zahtevom 5, ili ćelija u skladu sa patentnim zahtevom 7 za upotrebu u lečenju kancera, poželjno u obliku vakcine.
    11. Peptid za upotrebu u skladu sa patentnim zahtevom 9, naznačeno time što je navedeni karcinom odabran od: astrocitoma, pilocitnog astrocitoma, disembrioplastični neuroepitelijalni tumor, oligodendrogliomi, ependimom, glioblastoma multiforme, mešoviti gliomi, oligoastrocitomi, meduloblastom, retinoblastom, neuroblastom, germinom, teratom, gangliogliomi, gangliocitom, centralni gangliocitom, primitivni neuroektodermalni tumori (PNET, npr. meduloblastom, meduloepiteliom, neuroblastom, retinoblastom, ependimoblastom), tumori parenhima epifize (npr. pineocitom, pineoblastom), tumori ependimalnih ćelija, tumori horoidnog pleksusa, neuroepitelijalni tumori nejasnog porekla (npr. gliomatoza mozga, astroblastom), glioblastom, tumor prostate, karcinom dojke, karcinom jednjaka, karcinom debelog creva, kolorektalni karcinom, karcinom bubrežnih ćelija, svetloćelijski karcinom bubrežnih ćelija, karcinom pluća, CNS-a, jajnika, melanom, karcinom pankreasa, karcinom skvamoznih ćelija, leukemija i meduloblastom, i drugi tumori ili karcinomi koji pokazuju prekomernu ekspresiju survivina.
    12. Peptid za upotrebu u skladu sa patentnim zahtevom 9 ili 10 u kombinaciji sa najmanje jednim peptidom odabranim iz grupe koja sadrži ID BR. SEKV 4 do 13 za lečenje karcinoma bubrega, ili u kombinaciji sa najmanje jednim peptidom odabranim iz grupe koja sadrži ID BR. SEKV 4, 8, 11, 12 i 15 do 23 za lečenje karcinoma debelog creva.
    13. Komplet, koji se sastoj i od:
    (a) posude koja sadrži farmaceutsku smešu koja sadrži peptid u skladu sa bilo kojim od patentnih zahteva od 1 do 4, nukleinsku kiselinu ili vektor ekspresije u skladu sa patentnim zahtevom 5, ili ćeliju u skladu sa patentnim zahtevom 7, u rastvoru ili liofiliziranom obliku; (b) opciono, drugu posudu koja sadrži rastvarač ili rastvor za rekonstituciju za liofiliziranu formulaciju;
    (d) opciono, najmanje jedan peptid odabranog iz grupe koja se sastoji od ID BR. SEKV 4 do 23, i
    (e) opciono, uputstva za upotrebu rastvora i/ili rekonstituciju i/ili upotrebu liofilizirane formulacije.
RS20150093A 2008-05-14 2008-05-14 Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana RS53872B2 (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08008944.4A EP2119726B2 (en) 2008-05-14 2008-05-14 Novel and powerful MHC-class II peptides derived from survivin and neurocan

Publications (2)

Publication Number Publication Date
RS53872B1 RS53872B1 (sr) 2015-08-31
RS53872B2 true RS53872B2 (sr) 2018-06-29

Family

ID=39789337

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20150093A RS53872B2 (sr) 2008-05-14 2008-05-14 Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana

Country Status (24)

Country Link
US (5) US8647629B2 (sr)
EP (3) EP2119726B2 (sr)
JP (1) JP5663473B2 (sr)
KR (2) KR101602024B1 (sr)
CN (1) CN102027006B (sr)
AU (1) AU2009248413B2 (sr)
BR (2) BR122019014468B8 (sr)
CA (1) CA2724198C (sr)
CY (2) CY1115999T1 (sr)
DK (2) DK2119726T5 (sr)
EA (1) EA019603B1 (sr)
ES (2) ES2532896T5 (sr)
HK (1) HK1209757A1 (sr)
HR (2) HRP20151135T4 (sr)
HU (2) HUE024541T2 (sr)
MX (1) MX2010012443A (sr)
NO (1) NO2119726T3 (sr)
NZ (1) NZ588605A (sr)
PL (2) PL2119726T5 (sr)
PT (2) PT2119726E (sr)
RS (1) RS53872B2 (sr)
SI (2) SI2119726T2 (sr)
UA (1) UA103481C2 (sr)
WO (1) WO2009138236A1 (sr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023598A2 (en) 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
EP2113253B1 (en) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
MX344559B (es) 2008-04-29 2016-12-20 Ascendis Pharma As Compuestos de hormona de crecimiento humana recombinante unidos al peg.
ES2532896T5 (es) † 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
MX337432B (es) 2009-12-15 2016-03-04 Ascendis Pharma As Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
CA2821582A1 (en) * 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CN102181401B (zh) * 2011-02-01 2013-04-24 北京市肿瘤防治研究所 存活素酶联免疫试剂盒及其应用
KR20140100419A (ko) * 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
WO2015066057A2 (en) * 2013-10-28 2015-05-07 Baylor College Of Medicine Expansion of cmv-specific t cells from cmv-seronegative donors
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201321242D0 (en) * 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
SG11201703870UA (en) 2014-11-18 2017-06-29 Ascendis Pharma Endocrinology Div As Novel polymeric hgh prodrugs
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
LT3388075T (lt) * 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
MA54884A (fr) * 2015-07-01 2022-01-12 Immatics Biotechnologies Gmbh Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
CR20230563A (es) * 2015-07-06 2024-01-22 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-0579)
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
PH12022551111A1 (en) * 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
PE20230343A1 (es) * 2015-12-11 2023-03-01 Immatics Biotechnologies Gmbh Peptidos que estimulan respuestas inmunitarias antitumorales
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
PL3429618T3 (pl) 2016-03-16 2024-07-01 Amal Therapeutics Sa Kombinacja modulatora immunologicznego punktu kontrolnego i kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do zastosowania w medycynie
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
GB201604755D0 (en) * 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
GB201609193D0 (en) * 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
EP3475706B1 (en) * 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
MX2019000180A (es) * 2016-06-28 2019-11-05 Geneius Biotechnology Inc Composiciones de células t para la inmunoterapia.
HUE067838T2 (hu) 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
SI3573647T1 (sl) 2017-01-27 2023-07-31 Immatics Biotechnologies Gmbh Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka
US10738100B2 (en) 2017-01-27 2020-08-11 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN110651189B (zh) 2017-03-03 2024-10-25 特雷斯生物有限公司 肽疫苗
MX2019015879A (es) * 2017-07-07 2020-02-07 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinacones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluyendo el nsclc, el sclc y otros canceres.
US10800823B2 (en) * 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
KR102823291B1 (ko) 2017-10-09 2025-06-19 엔터롬 에스.에이. 종양-관련된 항원 에피토프의 미생물 서열 변이체
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3703723A4 (en) 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
HRP20230007T1 (hr) 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
JP7644000B2 (ja) * 2018-05-15 2025-03-11 インテルク ペプチド セラピューティクス リミテッド 活性化剤
JP7386852B2 (ja) * 2018-05-15 2023-11-27 インテルク ペプチド セラピューティクス リミテッド ペプチド活性化剤
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
AU2020233198B2 (en) 2019-03-04 2025-05-15 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
FI4021487T3 (fi) 2019-11-15 2024-02-06 Enterome S A Antigeenisiä peptidejä b-solun pahanlaatuisuuden ehkäisyyn ja hoitoon
CN113045635B (zh) * 2019-12-26 2025-12-16 上海细胞治疗集团股份有限公司 一种特异性结合hla-a2分型的多肽组合物及应用
CA3173666A1 (en) * 2020-04-14 2021-10-21 Claude Perreault Novel tumor-specific antigens for acute myeloid leukemia (aml) and uses thereof
TW202227621A (zh) 2020-11-19 2022-07-16 美商凱立凡爾免疫治療股份有限公司 重塑腫瘤微環境的溶瘤免疫療法
JP7661734B2 (ja) * 2021-03-19 2025-04-15 日本電気株式会社 検査システム及び検査方法
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
CA3229551A1 (en) * 2021-08-17 2023-02-23 Intomics A/S Vaccine design pipeline
AU2023246941A1 (en) 2022-03-31 2024-10-24 Enterome S.A. Antigenic peptides for prevention and treatment of cancer.
CN121759470A (zh) * 2024-09-30 2026-03-31 康希诺(上海)生物研发有限公司 一种关联杆状病毒凋亡抑制蛋白5的组合物及其制备方法和应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (sr) 1978-12-22 1994-02-03
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6255055B1 (en) * 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US6274362B1 (en) * 1999-02-04 2001-08-14 Millennium Pharmaceuticals, Inc. RGS-containing molecules and uses thereof
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2002353289A1 (en) 2001-12-13 2003-06-23 Koninklijke Philips Electronics N.V. Recommending media content on a media system
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
AU2003270311A1 (en) * 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
WO2005076009A2 (en) * 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
SI1806358T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se promiskuitetnovežejo na molekule humanega levkocitnega antigena HLA razreda II
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
AU2006311538A1 (en) † 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
EP2113253B1 (en) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
ES2532896T5 (es) † 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera

Also Published As

Publication number Publication date
SI2119726T1 (sl) 2015-05-29
CA2724198A1 (en) 2009-11-19
AU2009248413A1 (en) 2009-11-19
SI2119726T2 (en) 2018-03-30
DK2291395T3 (da) 2015-09-21
UA103481C2 (ru) 2013-10-25
DK2119726T3 (en) 2015-02-16
SI2291395T1 (sl) 2015-10-30
US11957729B2 (en) 2024-04-16
CA2724198C (en) 2016-03-22
SI2291395T2 (sl) 2019-03-29
KR101602024B1 (ko) 2016-03-09
KR20130041375A (ko) 2013-04-24
DK2291395T4 (en) 2019-02-18
HUE024541T2 (hu) 2016-01-28
KR101509284B1 (ko) 2015-04-10
DK2119726T5 (en) 2018-03-26
US10434136B2 (en) 2019-10-08
ES2532896T3 (es) 2015-04-01
HK1209757A1 (en) 2016-04-08
ES2549088T3 (es) 2015-10-22
JP5663473B2 (ja) 2015-02-04
HRP20151135T4 (hr) 2019-03-08
HRP20151135T1 (hr) 2015-11-20
CY1115999T1 (el) 2017-01-25
EA019603B1 (ru) 2014-04-30
ES2532896T5 (es) 2018-03-20
EP2119726A1 (en) 2009-11-18
EP2291395B1 (en) 2015-08-12
NO2119726T3 (sr) 2015-05-23
WO2009138236A1 (en) 2009-11-19
EP2291395A1 (en) 2011-03-09
PL2119726T5 (pl) 2018-04-30
EP2291395B2 (en) 2018-11-14
EP2119726B2 (en) 2017-11-29
HRP20150300T4 (hr) 2018-03-09
US20200078439A1 (en) 2020-03-12
NZ588605A (en) 2012-06-29
AU2009248413B2 (en) 2014-07-17
US20140127242A1 (en) 2014-05-08
KR20110021881A (ko) 2011-03-04
CN102027006A (zh) 2011-04-20
HK1156323A1 (en) 2012-06-08
CN102027006B (zh) 2016-01-13
EA201071297A1 (ru) 2011-04-29
ES2549088T5 (es) 2019-04-29
PT2119726E (pt) 2015-03-30
PL2119726T3 (pl) 2015-05-29
CY1117171T1 (el) 2017-04-05
BR122019014468B8 (pt) 2021-07-27
PL2291395T5 (pl) 2019-04-30
DK2119726T4 (en) 2018-02-19
HUE028102T2 (en) 2016-11-28
US20130323272A1 (en) 2013-12-05
PL2291395T3 (pl) 2016-01-29
US20140086943A1 (en) 2014-03-27
RS53872B1 (sr) 2015-08-31
MX2010012443A (es) 2010-12-20
US8647629B2 (en) 2014-02-11
HRP20150300T1 (hr) 2015-04-24
EP2899206A1 (en) 2015-07-29
EP2119726B1 (en) 2014-12-24
JP2011520436A (ja) 2011-07-21
PT2291395E (pt) 2015-10-23
BRPI0912622A2 (pt) 2016-05-03
US9498512B2 (en) 2016-11-22
BR122019014468B1 (pt) 2020-09-15
US20100029571A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
RS53872B2 (sr) Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
HRP20161504T1 (hr) Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
HRP20191009T1 (hr) Personalizirana imunoterapija protiv nekoliko neuronalnih i moždanih tumora
HRP20201467T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2019511214A5 (sr)
JP2021514178A5 (sr)
JP2017502076A5 (sr)
JP2016516789A5 (sr)
RU2010121967A (ru) Белковые каркасные структуры
JP2012504393A5 (sr)
JP2011520436A5 (sr)
Pechar et al. Coiled Coil Peptides and Polymer–Peptide Conjugates: Synthesis, Self-Assembly, Characterization and Potential in Drug Delivery Systems
CN105198964A (zh) 一种肿瘤靶向多肽、其制备方法及应用
Li et al. Chemical protein synthesis-assisted high-throughput screening strategies for D-peptides in drug discovery
CN110713522A (zh) 低pH插入肽的胞外段作为抗原的应用
CN105085631A (zh) 一种特异靶向her2蛋白的多肽及其应用
CN102911259A (zh) 一种修饰量子点的新型多肽配体
CN104130315A (zh) 一种特异靶向her2蛋白的多肽
CN108047312A (zh) 一种稳定多肽类蛋白靶向嵌合体分子及其制备方法和用途
CN105085632A (zh) 一种特异靶向egfr蛋白的多肽及其应用
Zyk et al. Choice of the optimal synthetic approach for the polypeptide ligands of prostatic specific membrane antigen preparation
Guo et al. Screening and identification of a specific peptide binding to hepatocellular carcinoma cells from a phage display peptide library
CN103910799B (zh) 一种基于抗egfr单链抗体及精氨酸九聚体的融合蛋白与应用
JP2010521441A5 (sr)